AR099907A1 - PHARMACEUTICAL COMPOSITION USED IN THE PREVENTION AND / OR TREATMENT OF DISEASES CAUSED AND / OR AGGRAVATED BY A DECREASE OR DEFICIENCY OF THE ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND / OR THE ACTIVATED BLOOD COAGULATION FACTOR VIII - Google Patents
PHARMACEUTICAL COMPOSITION USED IN THE PREVENTION AND / OR TREATMENT OF DISEASES CAUSED AND / OR AGGRAVATED BY A DECREASE OR DEFICIENCY OF THE ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND / OR THE ACTIVATED BLOOD COAGULATION FACTOR VIIIInfo
- Publication number
- AR099907A1 AR099907A1 ARP150100972A ARP150100972A AR099907A1 AR 099907 A1 AR099907 A1 AR 099907A1 AR P150100972 A ARP150100972 A AR P150100972A AR P150100972 A ARP150100972 A AR P150100972A AR 099907 A1 AR099907 A1 AR 099907A1
- Authority
- AR
- Argentina
- Prior art keywords
- blood coagulation
- coagulation factor
- factor viii
- polypeptide
- pharmaceutical composition
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un régimen de dosificación más efectivo o una composición farmacéutica para prevenir y/o tratar una enfermedad causada y/o agravada debido a una disminución o deficiencia de la actividad del factor de coagulación sanguínea VIII y/o del factor de coagulación sanguínea VIII activado. La administración de una composición farmacéutica que comprende una molécula de unión al antígeno biespecífica que reconoce al factor de coagulación sanguínea IX y/o al factor de coagulación sanguínea IX activado y al factor de coagulación sanguínea X y/o al factor de coagulación sanguínea X activado de acuerdo con un régimen de dosificación dado, permite prevenir y/o tratar mas eficazmente las enfermedades causadas y/o agravadas debido a una disminución o deficiencia de la actividad del factor de coagulación sanguínea VIII y/o del factor de coagulación sanguínea VIII activado. Reivindicación 1: Una composición farmacéutica para su uso en la prevención y/o el tratamiento de una enfermedad causada y/o agravada debido a una disminución o deficiencia de la actividad del factor de coagulación sanguínea VIII y/o del factor de coagulación sanguínea VIII activado, caracterizada porque dicha composición comprende una molécula de unión al antígeno biespecífica que reconoce al factor de coagulación sanguínea IX y/o al factor de coagulación sanguínea IX activado y al factor de coagulación sanguínea X y/o al factor de coagulación sanguínea X activado, en donde la molécula de unión al antígeno se administra a una dosis inicial de entre aproximadamente 0,001 y 100 mg/kg y se administra de manera continua varias veces a dosis continuas que son casi las mismas o menores que la dosis inicial, en donde el intervalo entre administraciones individuales es de por lo menos un día o más. Reivindicación 8: La composición farmacéutica de cualquiera de las reivindicaciones 1 a 7, caracterizada porque la molécula de unión al antígeno es el anticuerpo biespecífico que se describirá más adelante, en donde el primer polipéptido y el tercer polipéptido están asociados y el segundo polipéptido y el cuarto polipéptido están asociados: un anticuerpo biespecífico que comprende un primer polipéptido que es una cadena H que comprende la secuencia de aminoácidos de la SEQ ID Nº 20; un segundo polipéptido que es una cadena H que comprende la secuencia de aminoácidos de la SEQ ID Nº 25; un tercer polipéptido y un cuarto polipéptido que constituyen una cadena L compartida en común que comprende la secuencia de aminoácidos de la SEQ ID Nº 32.A more effective dosage regimen or a pharmaceutical composition for preventing and / or treating a disease caused and / or aggravated due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIII. The administration of a pharmaceutical composition comprising a bispecific antigen binding molecule that recognizes blood coagulation factor IX and / or activated blood coagulation factor IX and blood coagulation factor X and / or activated blood coagulation factor X according to a given dosage regimen, it allows to prevent and / or treat more effectively the diseases caused and / or aggravated due to a decrease or deficiency of the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIII. Claim 1: A pharmaceutical composition for use in the prevention and / or treatment of a disease caused and / or aggravated due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIII , characterized in that said composition comprises a bispecific antigen binding molecule that recognizes the blood coagulation factor IX and / or the activated blood coagulation factor IX and the blood coagulation factor X and / or the activated blood coagulation factor X, in where the antigen-binding molecule is administered at an initial dose of between about 0.001 and 100 mg / kg and is administered continuously several times at continuous doses that are almost the same or less than the initial dose, wherein the interval between Individual administrations is at least a day or more. Claim 8: The pharmaceutical composition of any one of claims 1 to 7, characterized in that the antigen binding molecule is the bispecific antibody that will be described below, wherein the first polypeptide and the third polypeptide are associated and the second polypeptide and the Fourth polypeptides are associated: a bispecific antibody comprising a first polypeptide that is an H chain comprising the amino acid sequence of SEQ ID No. 20; a second polypeptide that is an H chain comprising the amino acid sequence of SEQ ID No. 25; a third polypeptide and a fourth polypeptide that constitute a common shared L chain comprising the amino acid sequence of SEQ ID No. 32.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014127240 | 2014-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099907A1 true AR099907A1 (en) | 2016-08-24 |
Family
ID=58698528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100972A AR099907A1 (en) | 2014-06-20 | 2015-03-30 | PHARMACEUTICAL COMPOSITION USED IN THE PREVENTION AND / OR TREATMENT OF DISEASES CAUSED AND / OR AGGRAVATED BY A DECREASE OR DEFICIENCY OF THE ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND / OR THE ACTIVATED BLOOD COAGULATION FACTOR VIII |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR099907A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116284411A (en) * | 2023-02-03 | 2023-06-23 | 北京基科晟斯医药科技有限公司 | Antibody against recombinant human coagulation factor VIII-Fc fusion protein and application thereof |
-
2015
- 2015-03-30 AR ARP150100972A patent/AR099907A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116284411A (en) * | 2023-02-03 | 2023-06-23 | 北京基科晟斯医药科技有限公司 | Antibody against recombinant human coagulation factor VIII-Fc fusion protein and application thereof |
| CN116284411B (en) * | 2023-02-03 | 2024-02-13 | 北京基科晟斯医药科技有限公司 | Antibody against recombinant human coagulation factor VIII-Fc fusion protein and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105313A1 (en) | ANTI-BODY ANTI-CD137 THERAPEUTIC | |
| RU2017101705A (en) | PHARMACEUTICAL COMPOSITION INTENDED FOR APPLICATION FOR PREVENTION AND / OR TREATMENT OF A DISEASE THAT IS DEVELOPING OR PROGRESSING AS A RESULT OF REDUCTION OR LOSS OF SURVIVAL FACTOR | |
| EA201892075A1 (en) | COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS | |
| AR104213A1 (en) | ANTI-BODIES ANTI-CD38 AS THERAPEUTIC AGENTS | |
| AR104812A1 (en) | THERAPEUTIC COMBINATIONS AND METHODS TO TREAT NEOPLASIAS | |
| AR099698A1 (en) | ANTIBODIES AGAINST C5 THAT HAVE IMPROVED PHARMACOCINETICS | |
| BR112016012506A8 (en) | pharmaceutical combinations, their uses, and use of a data carrier | |
| MX2019012884A (en) | Combination therapy. | |
| BR112014021101A2 (en) | Antibody, pharmaceutical composition, combination drug, DNA and method of treating and/or preventing cancer, use of an antibody | |
| ECSP18073293A (en) | INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION | |
| BR112014021102A2 (en) | Antibody, pharmaceutical composition, combination drug, dna, treatment method and use of antibody | |
| JP2015517488A5 (en) | ||
| MX2019002510A (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x. | |
| AR050418A1 (en) | HER ANTIBODY FIXED DOSAGE | |
| AR103896A1 (en) | ANTI-PROTEIN FLT3 ANTI-PROTEIN DRUGS (ADC) | |
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| AR102595A1 (en) | ANTI-ANG2 ANTIBODIES AND METHODS OF USE | |
| MX2021002321A (en) | Novel methods. | |
| BR112018015367A2 (en) | nanofiber oromucosal carriers for therapeutic treatment | |
| MX2020008208A (en) | Fibroblast binding agents and use thereof. | |
| CO2019003865A2 (en) | Therapeutic protein | |
| MX2021002322A (en) | Novel methods. | |
| AR108790A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELIAC DISEASE, SENSITIVITY TO NON-CELIAC GLUTEN AND REFRACTORY CELIAC DISEASE | |
| EA202193276A1 (en) | METHODS FOR THE TREATMENT OF CHOLANGIOCARCINOMA | |
| RU2016133022A (en) | Means for the prevention and / or therapy of retinal inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |